Biotech

All Articles

FDA areas Kezar lupus test in grip adhering to 4 person deaths

.The FDA has placed Kezar Lifestyle Sciences' lupus test on hold after the biotech warned four death...

Phase 3 Scholar Stone trial strikes SMA target, sending stockpile 200%

.A period 3 trial of Academic Rock's back muscle degeneration (SMA) prospect has struck its own majo...

CAMP 4 is actually latest to eye IPO, while Upstream define $182M planning

.RNA biotech CAMP4 Rehabs has marked out prepare for a $67 thousand IPO, with inflammation-focused U...

Galecto acquires leukemia medicine, loses bone cancer asset in pivot

.A year after the failing of an idiopathic lung fibrosis prospect sent Galecto on a look for redempt...

Judo throws down $100M to knock out renal condition

.Taking the mat is actually Judo Biography, a promising biotech equipped along with $one hundred mil...

AstraZeneca pays CSPC $100M for preclinical heart disease medication

.AstraZeneca has paid off CSPC Drug Group $100 million for a preclinical heart attack drug. The deal...

Zephyrm finds Hong Kong IPO to money period 3 tissue therapy trials

.Zephyrm Bioscience is gusting toward the Hong Kong stock exchange, submitting (PDF) for an IPO to s...

Frazier Lifestyle Sciences collects $630M for small, mid-cap biotechs

.Frazier Daily life Sciences has actually sourced an even further $630 million for its own fund paid...

GigaGen gets up to $135M BARDA money to hammer botulism

.Antibody fan GigaGen, a subsidiary of Spanish biopharma Grifols, is increase its specialist to tack...

GPCR company Septerna files for IPO on durability of preclinical records

.Septerna is about to figure out exactly how a biotech without "any significant professional records...